These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21614902)

  • 21. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.
    Safra T; Menczer J; Bernstein R; Shpigel S; Inbar MJ; Grisaru D; Golan A; Levy T
    Gynecol Oncol; 2007 Apr; 105(1):205-10. PubMed ID: 17239430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study.
    Chen MD; Fleming GF; Mitchell S; Horowitz I
    Gynecol Oncol; 2006 Jan; 100(1):111-5. PubMed ID: 16150481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.
    Gossner G; Coleman RL; Mutch DG; Horowitz NS; Rader JS; Gibb RK; Powell MA; Herzog TJ
    Gynecol Oncol; 2006 Oct; 103(1):212-8. PubMed ID: 16677696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.
    Hochster H; Chen TT; Lu JM; Hills D; Sorich J; Escalon J; Ivy P; Liebes L; Muggia F
    Gynecol Oncol; 2008 Mar; 108(3):500-4. PubMed ID: 18191187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?
    Cheng X; Moroney JW; Levenback CF; Fu S; Jaishuen A; Kavanagh JJ
    J Chemother; 2009 Nov; 21(5):566-72. PubMed ID: 19933049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer: a meta-analysis.
    Möbus V; Kieback DG; Kaubitzsch SK
    Anticancer Res; 2007; 27(3B):1581-7. PubMed ID: 17595779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients.
    Calcagno M; Bellati F; Palaia I; Plotti F; Basile S; Pastore M; Sansone M; Arrivi C; Angioli R; Panici PB
    Int J Gynecol Cancer; 2009 Apr; 19(3):455-9. PubMed ID: 19407574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
    BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
    Bookman MA; Darcy KM; Clarke-Pearson D; Boothby RA; Horowitz IR
    J Clin Oncol; 2003 Jan; 21(2):283-90. PubMed ID: 12525520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
    Largillier R; Valenza B; Ferrero JM; Novo C; Creisson A; Lesbats G; Mari V; Hebert C; Chamorey E
    Oncology; 2007; 73(3-4):177-84. PubMed ID: 18418010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of two topotecan treatment schedules in patients with recurrent ovarian cancer.
    Bruchim I; Ben-Harim Z; Piura E; Haran G; Fishman A
    J Chemother; 2016 Apr; 28(2):129-34. PubMed ID: 27093640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study.
    McGonigle KF; Muntz HG; Vuky J; Paley PJ; Veljovich DS; Greer BE; Goff BA; Gray HJ; Malpass TW
    Cancer; 2011 Aug; 117(16):3731-40. PubMed ID: 21815133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
    Del Carmen MG; Supko JG; Horick NK; Rauh-Hain JA; Clark RM; Campos SM; Krasner CN; Atkinson T; Birrer MJ
    Cancer; 2016 Nov; 122(21):3297-3306. PubMed ID: 27421044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma.
    Aoki D; Katsumata N; Nakanishi T; Kigawa J; Fujiwara K; Takehara K; Kamiura S; Hiura M; Hatae M; Sugiyama T; Ochiai K; Noda K
    Jpn J Clin Oncol; 2011 Mar; 41(3):320-7. PubMed ID: 20974678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
    Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of continuous infusion topotecan in persistent and recurrent ovarian cancer.
    Elkas JC; Holschneider CH; Katz B; Li AJ; Louie R; McGonigle KF; Berek JS
    Int J Gynecol Cancer; 2003; 13(2):138-41. PubMed ID: 12657113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers.
    Markman M; Webster K; Zanotti K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 2004 Oct; 95(1):109-13. PubMed ID: 15385118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of topotecan as second-line therapy in patients with recurrent ovarian cancer.
    Beshara N; Fung Kee Fung M; Faught W
    Eur J Gynaecol Oncol; 2002; 23(4):287-90. PubMed ID: 12214724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoreduction of Progressive Intraocular Retinoblastoma by Systemic Topotecan.
    Sultan I; Hajja Y; Nawaiseh I; Mehyar M; Deebajah R; Jaradat I; Yousef YA
    Ophthalmic Genet; 2016 Jun; 37(2):209-13. PubMed ID: 26760494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of lower-dose topotecan in recurrent ovarian cancer: a retrospective case review.
    Mitchell SK; Carson LF; Judson P; Downs LS
    Int J Gynecol Cancer; 2005; 15(5):793-8. PubMed ID: 16174226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.